pSivida To Present at the 30th Annual ROTH Conference
March 05 2018 - 8:00AM
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
of sustained release drug products and technologies, announced
today that Nancy Lurker, President and Chief Executive Officer, is
scheduled to present an overview of the Company and its progress at
the 30th Annual ROTH Conference on Monday, March 12, 2018, at 5:00
p.m. ET. The conference will be held at the Ritz Carlton,
Laguna Nigel in Orange County, CA.
A live audio and/or webcast and subsequent archived replay of
pSivida's presentation may be accessed via the Investors section of
the Company's website under "Resources - Events &
Presentations" at www.psivida.com. The replay will be available for
90 days after the event.
About pSivida Corp.pSivida
Corp. (www.psivida.com), headquartered in Watertown, MA, is a
leader in the development of sustained release drug products for
treating eye diseases. pSivida has developed three of only four
sustained-release treatments for back-of-the-eye diseases approved
by the U.S. Food and Drug Administration (FDA). The most recent,
ILUVIEN®, a micro-insert for diabetic macular edema, licensed to
Alimera Sciences, is currently sold directly in the U.S. and
several EU countries. Retisert®, an implant for posterior segment
uveitis, is licensed to and sold by Bausch & Lomb. On January
5, 2018, a New Drug Application (NDA) for Durasert™ micro-insert
three-year treatment for posterior segment uveitis, was submitted
to the FDA. Two pivotal Phase 3 studies with Durasert achieved
their primary efficacy endpoint of prevention of recurrence of
uveitis at six months of follow-up with statistical significance.
pSivida's pre-clinical development program is focused on using its
core platform technology Durasert to deliver drugs to treat wet
age-related macular degeneration, glaucoma, osteoarthritis and
other diseases. To learn more about pSivida, please
visit www.psivida.com and connect on Twitter, LinkedIn,
Facebook and Google+.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties
and potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or
believe may occur in the future are forward-looking statements.
Some of the factors that could cause actual results to differ
materially from the anticipated results or other expectations
expressed, anticipated or implied in our forward-looking statements
include uncertainties with respect to: our ability to achieve
profitable operations and access to needed capital; fluctuations in
our operating results; successful commercialization of, and receipt
of revenues from, ILUVIEN® for diabetic macular edema ("DME"),
which depends on Alimera's ability to continue as a going concern;
Alimera's ability to obtain marketing approvals and the effect of
pricing and reimbursement decisions on sales of ILUVIEN; the number
of clinical trials and data required for the Durasert three-year
uveitis marketing approval application in the U.S.; acceptance of
the Durasert three-year uveitis NDA in the U.S.; our ability to use
data in a U.S. NDA from clinical trials outside the U.S.; our
ability to successfully commercialize Durasert three-year uveitis,
if approved, in the U.S.; potential off-label sales of ILUVIEN for
uveitis; consequences of fluocinolone acetonide side effects; the
development of our next-generation Durasert shorter-duration
treatment for posterior segment uveitis; potential declines in
Retisert® royalties; efficacy and our future development of an
implant to treat severe osteoarthritis; our ability to successfully
develop product candidates, initiate and complete clinical trials
and receive regulatory approvals; our ability to market and sell
products; the success of current and future license agreements,
including our agreement with Alimera; termination or breach of
current license agreements, including our agreement with Alimera;
our dependence on contract research organizations, vendors and
investigators; effects of competition and other developments
affecting sales of products; market acceptance of products; effects
of guidelines, recommendations and studies; protection of
intellectual property and avoiding intellectual property
infringement; retention of key personnel; product liability;
industry consolidation; compliance with environmental laws;
manufacturing risks; risks and costs of international business
operations; effects of the potential U.K. exit from the EU;
legislative or regulatory changes; volatility of stock price;
possible dilution; absence of dividends; and other factors
described in our filings with the Securities and Exchange
Commission. You should read and interpret any forward-looking
statements in light of these risks. Should known or unknown risks
materialize, or should underlying assumptions prove inaccurate,
actual results could differ materially from past results and those
anticipated, estimated or projected in the forward-looking
statements. You should bear this in mind as you consider any
forward-looking statements. Our forward-looking statements speak
only as of the dates on which they are made. We do not undertake
any obligation to publicly update or revise our forward-looking
statements even if experience or future changes makes it clear that
any projected results expressed or implied in such statements will
not be realized.
Contact:
Barbara Ryan –
InvestorBarbara@barbararyanadvisors.co203-274-2825
Thomas Gibson –
Mediatom@tomgibsoncommunications.com 201-476-0322
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024